ACT is a publicly-traded biotechnology company
• Develop cellular therapies for the treatment of diseases and conditions that impact hundreds of millions of people worldwide
• Cell therapies are traditionally derided for being high cost, high touch and having lack of scalability. Not our approach at all
• Premier scientific and research development team
About ACT:
– Ticker – ACTC
– Market Capitalization: $170 million
– Principal lab and GMP facility: Marlborough, MA
– Corporate HQ: Santa Monica, CA
– Only hESC-derived tissue trials ongoing worldwide
– Nearly completed corporate turnaround from disastrous financial and legal decisions